Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
DKN-01 + folinic acid + fluorouracil + irinotecan + oxaliplatin + bevacizumab
- Development stage
- Unknown
- Lead developer
- Leap Therapeutics
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
**DKN-01 + folinic acid + fluorouracil + irinotecan + oxaliplatin + bevacizumab** is an investigational combination therapy designed for advanced gastroesophageal adenocarcinomas and potentially other gastrointestinal cancers. DKN-01 is a humanized IgG4 monoclonal antibody that binds and neutralizes Dickkopf-related protein 1 (DKK1), a Wnt/PI3K pathway modulator associated with poor prognosis and immunosuppressive tumor microenvironment. The combination includes folinic acid (leucovorin), fluorouracil (5-FU), irinotecan, oxaliplatin—standard components of FOLFIRINOX or FOLFOX/FOLFIRI chemotherapy—and bevacizumab, a vascular endothelial growth factor inhibitor. DKN-01 enhances PD-1 blockade efficacy by promoting anti-tumor immune infiltration and may benefit patients with high tumor DKK1 expression.
02
Targets
DKK1 (Dickkopf-related protein 1)
Beyond the preview
Go deeper on DKN-01 + folinic acid + fluorouracil + irinotecan + oxaliplatin + bevacizumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on DKN-01 + folinic acid + fluorouracil + irinotecan + oxaliplatin + bevacizumab.